Home » News » 12/05 » Wyeth Pharmaceuticals submits extended release antidepressant to FDA

Wyeth Pharmaceuticals submits extended release antidepressant to FDA

Date published: 29/12/2005

Wyeth Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for desvenlafaxine extended release (DVS-233) for the treatment of major depressive disorder (MDD).

The new treatment is designed for the treatment of major depressive disorder in patients with a broad range of symptoms associated with depression, including both emotional and somatic symptoms.

"We know from clinical studies as well as clinical practice that there remain significant unmet needs in treating depressed patients," said Gary Stiles, executive vice president, chief medical officer, Wyeth.

"If approved, desvenlafaxine extended release will offer physicians a new clinically proven option for treating depression."

Depression is the most common serious mental disorder worldwide and affects approximately 121 million people, making it the fourth leading cause of disability and premature death.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.